100944-91-0

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(chloromethoxymethyl)-4-methylbenzene is used as an intermediate for the synthesis of various pharmaceuticals. Its chloromethyl group allows for participation in a range of chemical reactions, making it a valuable building block in the development of new drugs.
Used in Agrochemical Production:
In the agrochemical industry, 1-(chloromethoxymethyl)-4-methylbenzene is utilized as an intermediate in the creation of different agrochemicals, contributing to the development of products that enhance agricultural productivity and crop protection.
Used in Organic Compound Research and Development:
1-(chloromethoxymethyl)-4-methylbenzene is also employed in research and development for the production of a variety of organic compounds. Its reactivity and structural features make it a useful compound for exploring new chemical pathways and synthesizing novel organic molecules.

Upstream product

• 100944-86-3 4-methylbenzyl methylthiomethyl ether 
• 589-18-4 4-Methylbenzyl alcohol 
• 50-00-0 formaldehyd 

Downstream Products

• 1384441-88-6 Cl^(1-)*C₁₅H₁₇N₂O₂⁽¹⁺⁾ 
• 1384441-79-5 4-(hydroxyiminomethyl)-1-(4-methylbenzyloxymethyl)pyridinium chloride 
• 136160-28-6 5-Ethyl-1-(4-methyl-benzyloxymethyl)-6-phenylsulfanyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 699-02-5 4-Methylphenethyl alcohol 

Relevant academic research and scientific papers

6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase

3-Hydroxypyrimidine-2,4-dione (HPD) represents a versatile chemical core in the design of inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated RNase H and integrase strand transfer (INST). We report herein the design, synthesis and biological evaluation of an HPD subtype (4) featuring a cyclohexylmethyl group at the C-6 position. Antiviral testing showed that most analogues of 4 inhibited HIV-1 in the low nanomolar to submicromolar range, without cytotoxicity at concentrations up to 100?μM. Biochemically, these analogues dually inhibited both the polymerase (pol) and the RNase H functions of RT, but not INST. Co-crystal structure of 4a with RT revealed a nonnucleoside RT inhibitor (NNRTI) binding mode. Interestingly, chemotype 11, the synthetic precursor of 4 lacking the 3-OH group, did not inhibit RNase H while potently inhibiting pol. By virtue of the potent antiviral activity and biochemical RNase H inhibition, HPD subtype 4 could provide a viable platform for eventually achieving potent and selective RNase H inhibition through further medicinal chemistry.

[1,2]-Wittig rearrangement from chloromethyl ethers

The reaction of different chloromethyl ethers 1 with an excess of lithium powder and a catalytic amount of 4,4′-di-tert-butylbiphenyl (2.5 mol %) in THF at 0 °C leads to the corresponding α-lithiomethyl ether intermediates, through a chlorine-lithium exchange, which spontaneously undergo a clean [1,2]-Wittig rearrangement affording the expected homobenzylic alcohols 2. This is the first version of this rearrangement starting from easily available chloromethyl ethers.

Pyrimidinones as reversible metaphase arresting agents

5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase.Highly active compounds have a heteroatom (O, S or N) in the β-position of the N(1)-carbon chain which is further substituted by an aryl gr